Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1

seekingalpha.com/news/4525149-can-novo-hurt-lilly-rally-alzheimers-data-glp-1

Lilly’s (LLY) recent climb to reach a $1T market cap will come under scrutiny in the coming days when Novo Nordisk (NVO) posts late-stage trial data showing how Rybelsus, its diabetes pill containing semaglutide, the active ingredient of Wegovy, could
Quick Insights
A successful trial…

This story appeared on seekingalpha.com, 2025-11-23 13:41:03.240000.
The Entire Business World on a Single Page. Free to Use →